Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07553429

A First-in-human Study to Evaluate Safety and Tolerability of Multiple Intravitreal Doses of BI 3812465 in Adults With Center-involved Diabetic Macular Edema

Led by Boehringer Ingelheim · Updated on 2026-06-03

49

Participants Needed

30

Research Sites

15 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating how well different doses of a medicine called BI 3812465 are tolerated by adults with diabetic macular edema that affects the center of the eye. This is the first time BI 3812465 is given to humans. The study is designed in two parts: an initial phase with a small group receiving increasing doses and a second phase with a larger group randomized to low, medium, or high doses. Participants receive BI 3812465 as injections into the back of the eye, with a total of three eye injections administered. In Part 1, participants start with low doses and may move to higher doses if tolerated. In Part 2, participants are randomly assigned to one of three dose groups. The study follows participants for up to seven months, including the dosing and observation periods. During the study, participants visit the study site 19 times, with some visits possibly conducted at home when feasible. At these visits, doctors assess the severity of the eye condition and monitor any health problems that may be caused by the medicine. The main outcomes include monitoring for dose-limiting events and ocular adverse events over up to 169 days from the first drug administration.

CONDITIONS

Brief Title

A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years or older
  • Diagnosis of diabetes mellitus type 1 or type 2 under regular treatment with HbA1c less than 12%
  • Center-involved diabetic macular edema confirmed by retinal imaging with central subfield thickness of 320 micrometers or more
  • Clear enough ocular media and good pupil dilation for quality eye imaging
  • Willingness and ability to understand study procedures and risks
  • Signed informed consent prior to any study procedures
  • Women of childbearing potential must use highly effective birth control
  • Men must use contraception or abstain to prevent pregnancy of a partner
Not Eligible

You will not qualify if you...

  • Only one functional eye; the other eye must support daily functioning
  • Active proliferative diabetic retinopathy
  • Active retinal neovascularization requiring acute treatment
  • Active neovascularization of the iris or anterior chamber angle (except small iris tufts)
  • Additional eye diseases that may affect study participation such as uncontrolled glaucoma or high intraocular pressure over 24 mmHg despite treatment
  • History of high myopia greater than 8 diopters in the study eye
  • Eye abnormalities that prevent adequate detection of inflammation or other pathologies
  • Previous ocular gene or cell therapy
  • Use of corticosteroids locally or systemically within 1 month before screening
  • Absence of the posterior capsule (aphakia) or recent YAG laser capsulotomy within 2 months
  • Other conditions that might interfere with study outcomes as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 169 days

Participants receive multiple intravitreal doses of BI 3812465 at low, medium, or high doses to evaluate safety and tolerability.

Multiple visits for dosing and assessments during treatment period

Trial Site Locations

Total: 30 locations

1

Associated Retina Consultants, Ltd.

Phoenix, Arizona, United States, 85020

Not Yet Recruiting

2

Research Network Arizona

Scottsdale, Arizona, United States, 85255

Not Yet Recruiting

3

Win Retina

Arcadia, California, United States, 91006

Not Yet Recruiting

4

California Retina Consultants-Bakersfield-65523

Bakersfield, California, United States, 93309

Not Yet Recruiting

5

Retina-Vitreous Associates Medical Group

Beverly Hills, California, United States, 90211

Not Yet Recruiting

6

Global Research Management

Glendale, California, United States, 91204

Actively Recruiting

7

Retina Associates of Southern California

Huntington Beach, California, United States, 92647

Not Yet Recruiting

8

Retinal Consultants Medical Group

Sacramento, California, United States, 95825

Not Yet Recruiting

9

Bay Area Retina Associates - Walnut Creek

Walnut Creek, California, United States, 94598

Not Yet Recruiting

10

Retina Group of New England, PC

Waterford, Connecticut, United States, 06385

Not Yet Recruiting

11

Retina Group of Florida - Fort Myers Retina Center

Fort Myers, Florida, United States, 33912

Not Yet Recruiting

12

Florida Retina Consultants

Lakeland, Florida, United States, 33805

Not Yet Recruiting

13

East Florida Eye Institute

Stuart, Florida, United States, 34994

Not Yet Recruiting

14

Florida Retina Institute Wildwood

Wildwood, Florida, United States, 34785

Not Yet Recruiting

15

Cumberland Valley Retina Consultants

Hagerstown, Maryland, United States, 21740

Not Yet Recruiting

16

Ophthalmic Consultants of Long Island

Oceanside, New York, United States, 11572

Not Yet Recruiting

17

North Carolina Retina Associates

Wake Forest, North Carolina, United States, 27587

Not Yet Recruiting

18

Red River Research Partners, LLC

Fargo, North Dakota, United States, 58103

Not Yet Recruiting

19

Verum Research, LLC

Eugene, Oregon, United States, 97401

Not Yet Recruiting

20

EyeHealth Northwest

Portland, Oregon, United States, 97225

Not Yet Recruiting

21

Tennessee Retina

Nashville, Tennessee, United States, 37203

Not Yet Recruiting

22

Austin Clinical Research, LLC

Austin, Texas, United States, 78750

Not Yet Recruiting

23

Retina Consultants of Texas-Bellaire-67493

Bellaire, Texas, United States, 77401

Not Yet Recruiting

24

Valley Retina Institute, PA

McAllen, Texas, United States, 78503

Not Yet Recruiting

25

Medical Center Ophthalmology Associates

San Antonio, Texas, United States, 78240

Not Yet Recruiting

26

Retina Consultants of Texas - San Antonio Medical Center

San Antonio, Texas, United States, 78240

Not Yet Recruiting

27

Retina Consultants of Texas-The Woodlands-67575

The Woodlands, Texas, United States, 77384

Not Yet Recruiting

28

Strategic Clinical Research Group

Weatherford, Texas, United States, 76087

Not Yet Recruiting

29

Emerson Clinical Research Institute

Falls Church, Virginia, United States, 22042

Not Yet Recruiting

30

Emanuelli Research & Development Center

Arecibo, Puerto Rico, 00612

Not Yet Recruiting

Loading map...

Research Team

B

Boehringer Ingelheim

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

6

Similar Trials

Randomized, Double-blind Study Comparing Ranibizumab 10mg/ml...

Diabetic Macular Edema

Actively Recruiting

1 location

Real-World, Long-Term Data Collection to Gain Clinical Insig...

Neovascular Age-related Macular Degeneration

Actively Recruiting

59 locations

A Phase 1b Open-Label, Multiple Ascending Dose Study of the ...

Diabetic Macular Edema

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here